**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 66512

**Manuscript Type:** MINIREVIEWS

**Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?**

Biolato M *et al*. Portal vein thrombosis

Marco Biolato, Mattia Paratore, Luca Di Gialleonardo, Giuseppe Marrone, Antonio Grieco

**Marco Biolato, Giuseppe Marrone, Antonio Grieco,** Internal and Liver Transplant Medicine Unit, CEMAD, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00168, Italy

**Marco Biolato, Mattia Paratore, Luca Di Gialleonardo, Giuseppe Marrone, Antonio Grieco,** Institute of Internal Medicine, Catholic University of Sacred Heart, Rome 00168, Italy

**Author contributions:** Biolato M and Paratore M wrote the paper; Paratore M and Di Gialleonardo L performed literature analysis; Marrone G and Grieco A revised the paper for important intellectual content.

**Corresponding author: Marco Biolato, MD, PhD, Staff Physician,** Internal and Liver Transplant Medicine Unit, CEMAD, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A Gemelli 8, Rome 00168, Italy. marco.biolato@policlinicogemelli.it

**Received:** March 30, 2021

**Revised:** September 22, 2021

**Accepted:** April 3, 2022

**Published online:** April 27, 2022

**Abstract**

In recent years, the traditional concept that cirrhosis-related coagulopathy is an acquired bleeding disorder has evolved. Currently, it is known that in cirrhotic patients, the hemostatic system is rebalanced, which involves coagulation factors, fibrinolysis and platelets. These alterations disrupt homeostasis, skewing it toward a procoagulant state, which can lead to thromboembolic manifestations, especially when hemodynamic and endothelial factors co-occur, such as in the portal vein system in cirrhosis. Portal vein thrombosis is a common complication of advanced liver cirrhosis that negatively affects the course of liver disease, prognosis of cirrhotic patients and success of liver transplantation. It is still debated whether portal vein thrombosis is the cause or the consequence of worsening liver function. Anticoagulant therapy is the mainstay treatment for acute symptomatic portal vein thrombosis. In chronic portal vein thrombosis, the role of anticoagulant therapy is still unclear. Traditional anticoagulants, vitamin K antagonists and low-molecular-weight heparin are standard-of-care treatments for portal vein thrombosis. In the last ten years, direct oral anticoagulants have been approved for the prophylaxis and treatment of many thromboembolic-related diseases, but evidence on their use in cirrhotic patients is very limited. The aim of this review was to summarize the evidence about the safety and effectiveness of direct oral anticoagulants for treating portal vein thrombosis in cirrhotic patients.

**Key Words:** Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Bleeding

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Biolato M, Paratore M, Di Gialleonardo L, Marrone G, Grieco A. Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence? *World J Hepatol* 2022; 14(4): 682-659

**URL**: https://www.wjgnet.com/1948-5182/full/v14/i4/682.htm

**DOI**: https://dx.doi.org/10.4254/wjh.v14.i4.682

**Core Tip:** The role of anticoagulant therapy in portal vein thrombosis is still unclear, especially in partial, chronic and asymptomatic thrombosis. Vitamin K antagonists and low-molecular-weight heparin were demonstrated to be safe and effective, with a positive influence on liver function, portal hypertension and mortality. Direct oral anticoagulants are a new approach to treat portal vein thrombosis in patients with cirrhosis and have many advantages compared to classic anticoagulants, although evidence is still limited. In patients awaiting liver transplantation, dabigatran may be promising for preventing thrombosis progression because of the low rate of hepatotoxicity, predominant renal metabolism and reversibility in perioperative management.

**INTRODUCTION**

***Portal vein thrombosis***

Portal vein thrombosis (PVT) is defined as the presence of a thrombus within the portal vein, either in the main trunk or intrahepatic branches, which can extend to the splenic or superior mesenteric vein (SMV). Based on the degree of obstruction, PVT can be characterized as occlusive or nonocclusive. Based on onset, PVT can be classified as acute or chronic. Acute PVT includes a symptomatic onset and the exclusion of portoportal collaterals with imaging, while chronic PVT is defined as previously diagnosed PVT or as PVT associated with long-lasting signs of thrombosis such as cavernoma. A temporal cutoff dividing acute and chronic DVT has not been defined[1,2].

***Prevalence and incidence***

The heterogeneity of PVT incidence and prevalence is related to multiple factors, among the most important of which are cirrhosis severity, the clinical presentation of PVT and diagnostic techniques used to identify PVT. The analysis of a large multicenter study, which included 1243 cirrhotic patients with Child-Pugh A (863) or B (380), showed that the cumulative PVT incidence was 4.6%, 8.2% and 10.7% at the 1-, 3- and 5-year follow-up, respectively[3]. However, in advanced cirrhosis, the annual incidence was higher and ranged from 10% to 15%[1].

In the “Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry” (PRO-LIVER) prospective multicenter study, the PVT prevalence in 753 cirrhotic patients who underwent Doppler ultrasound was 17%, and Child-Pugh B or C, hepatocellular carcinoma (HCC), previous PVT and gastrointestinal bleeding were independently associated with PVT, suggesting that there was a correlation between the progression of disease and PVT[4]. Interestingly, in this study, 45 patients who developed PVT received anticoagulant therapy. According to Zhang *et al*[5], the prevalence was higher in advanced cirrhosis with acute decompensation than in compensated cirrhosis (9.36% *vs* 5.24%). Acute PVT seems to be more common than chronic PVT in cirrhosis[6]. This is likely related to the clinical presentation of acute PVT *vs* chronic PVT.

In the setting of liver transplantation, the prevalence of PVT ranges from 2% to 26%[7]. Francoz *et al*[8] described a prevalence of 8.4% at the time of listing for transplantation and an annual incidence of 3.2% in patients without PVT at the time of listing.

In another retrospective study on approximately 400 Liver transplant candidates, the prevalence of PVT was 10.3%, of which 25% had PVT at the time of listing for transplantation, 17.5% developed PVT while waiting for transplantation and 57.5% were diagnosed with PVT during surgery[9].

***Pathophysiology and risk factors for PVT***

In noncirrhotic patients, PVT is uncommon and can occur more frequently in association with inherited or acquired thrombophilia. Major risk factors for PVT in noncirrhotic patients are myeloproliferative disorders, prothrombin gene G20210A mutation and antiphospholipid syndrome[10].

In cirrhotic patients, multiple systemic and local factors contribute to an increased risk of PVT. Recent evidence changed the traditional understanding that cirrhotic patients acquired bleeding disorders due to reduced levels of procoagulant factors. In chronic liver disease, the fragile rebalance of the hemostatic system involves coagulation factors, platelets and fibrinolysis. Regarding the coagulation system, a parallel modification of both prohemostatic and antihemostatic factors takes place. Antithrombin and protein C reductions[11,12] and factor VIII increases were shown[12], and low fibrinogen levels and low factor II, V, VII, IX, X and XI levels were demonstrated[12]. Concerning platelets, thrombocytopenia due to sequestration, a shortened half-life and reduced production[13] may shift the balance toward bleeding. Instead, high levels of von Willebrand factor (vWF) and reductions in its cleavage factor, ADAMTS 13[14], promote thrombosis. Finally, the fibrinolytic system is rebalanced, with some alterations, such as low plasmin inhibitor levels promoting fibrinolysis, and other alterations, such as low plasminogen contrast fibrinolysis[14]. In liver cirrhosis, fibrinogen production is relatively unchanged, but functional fibrinogen levels are reduced. This functional defect is called acquired dysfibrinogenemia and is caused by the inadequate removal of excess sialic acid residues from fibrinogen, resulting in fibrin polymerization impairment[15,16].

How is procoagulant imbalance in this setting possible? In 2011, Tripodi *et al*[17] demonstrated that protein C reduction (caused by reduced liver synthetic activity) and factor VIII increases (caused by vWF increases), which binds and protects factor VIII and reduces low-density lipoprotein-related protein and triggers resistance to thrombomodulin activity, which is one of the most important anticoagulant factors. Thus, it is not surprising that a decrease in protein C (PC) causes an increase in factor VIII (FVIII) levels, and the FVIII/PC ratio predicts unfavorable outcomes in cirrhotic patients[18]. However, recent developments in this field suggest that in reality, coagulopathy in cirrhotic patients is much more complicated than previously thought (as described by the classic view), and classic tests used to determine this state are inaccurate. Therefore, new tools to detect cirrhosis-related coagulopathy, which consider antithrombin, protein C and FVIII, are needed. One of the most promising tests is the thrombin generation assay[19].

Hemodynamic factors play an important role in PVT development. A decrease in portal vein blood flow velocity of less than 15 cm/second is closely related to PVT development in liver cirrhosis[20-22]. Considering this, all conditions that reduce the velocity of portal flow can promote PVT development, such as nonselective beta blockers (NSBBs) or the presence of portosystemic shunts. NSBBs reduce the portal pressure gradient by decreasing cardiac output and inducing unopposed alpha-1 adrenergic-mediated splanchnic vasoconstriction, and they are widely used for the primary and secondary prophylaxis of variceal bleeding[23,24]. A recent meta-analysis showed that NSBBs significantly increased PVT risk in cirrhosis. In this study, the authors suggest ultrasound follow-up to estimate portal vein blood flow in patients treated with long-term NSBBs[25]. Portosystemic shunts open when portal pressure increases to deviate the portal flow to the inferior vena cava through various collateral circles. The convergence of portal blood flow into these vessels, called the “steal effect”, slows the portal flow velocity and is associated with a major risk of PVT, as found by Maruyama *et al*[26].

Inherited thrombophilic disorders, such as prothrombin gene G20210A polymorphisms[27], deficiencies of antithrombin, protein C and protein S, factor V Leiden[28], or lupus anticoagulant[29], increase PVT risk in patients with cirrhosis[30], but the low prevalence of these conditions does not justify screening to search for these alterations[31,32]. Other risk factors were associated with PVT in cirrhosis. Some evidence has demonstrated that the presence of endothelial damage predisposes patients to thrombosis[33]. This damage could be related to higher intestinal permeability and higher gut-derived bacterial lipopolysaccharide (LPS)[34], which also stimulate endothelial cells to produce and release factor VIII[35].

Intrabdominal surgery, especially splenectomy, significantly affects the development of PVT[5]. The etiology of liver disease may be associated with major PVT risk, such as nonalcoholic fatty liver disease (NAFLD)[21] or with a lower risk of PVT in cases of alcoholic cirrhosis, which might be correlated with the effect of alcohol on coagulant function and vitamin status[36].

Sarin *et al*[37] proposed a model to assess the pretest probability of PVT. It is based on major criteria, such as Child-Pugh B or C, PVT history and presence of prothrombotic risk mutations, and minor criteria, such as new onset or worsening of portal hypertension, reduction in portal flow velocity < 15 cm/second, evidence of portosystemic shunt, active HCC, history of VTE, recent abdominal intervention, and acute abdominal clinical manifestations. The presence of 2 major, 1 major and 2 minor, or the presence of 4 minor criteria, suggests a high risk for PVT development[37]. This score could help clinicians understand which patient could benefit from anticoagulant prophylaxis, but prospective trials are needed to establish the score’s predictive role.

***Clinical manifestations***

The clinical presentation of PVT depends mainly on two factors: the extent of thrombotic occlusion, partial or complete, and the time of thrombus formation, acute or chronic.

Acute PVT typically presents with gastrointestinal symptoms (due to splanchnic congestion), such as abdominal pain, nausea and vomiting, up to severe gastrointestinal complications, such as bleeding, sepsis and lactic acidosis[38]. Splenomegaly is frequent, ascites is rare[39]. The symptoms can be more severe and prognosis unfavorable in cases of complete mesenteric thrombosis[6].

Chronic PVT is often asymptomatic and is usually accidentally discovered during radiological examinations performed for other reasons[40,41]. The clinical presentation of chronic PVT is related to manifestations of portal hypertension, such as ascites, hepatic encephalopathy, gastroesophageal variceal bleeding[6] and hypersplenism with pancytopenia[39]. In addition, neovessel formation and cavernomatosis can alter the anatomy of biliary ducts. The effects of these alterations can manifest with portal cholangiopathy, characterized by pruritus, obstructive jaundice and cholangitis, or “pseudocholangiocarcinoma”, a tangle of neovessels mimicking cholangiocarcinoma cancer[39].

***Diagnosis and staging of PVT***

Doppler ultrasound is the most common diagnostic technique for PVT, with high sensitivity and specificity[40]. Generally, diagnosis with ultrasound occurs during screening for HCC in asymptomatic patients but should be performed in patients with suggestive symptoms[42] or in patients with deteriorating hepatic decompensation[1]. Normal PV flow excludes PVT, while positive results need further evaluations with second-level imaging techniques, such as CT or MRI, to confirm the presence of acute or chronic PVT[22], to exclude the presence of a neoplastic thrombus and to examine thrombus extension. Sherman *et al*[43] proposed a scoring system called A-VENA, which considers venous expansion, thrombus enhancement, neovascularity, tumors adjacent to the thrombus and alpha-fetoprotein levels to distinguish a tumor thrombus from a nonneoplastic thrombus in HCC patients being evaluated for liver transplantation.

A recent review and meta-analysis investigated the diagnostic value of contrast-enhanced ultrasound (CEUS) to differentiate PVT from neoplastic invasion in HCC. It was demonstrated that CEUS has excellent accuracy and could be considered a valid alternative to second-level imaging techniques[44]. In some cases, it is necessary to perform a histological exam of the thrombus to distinguish a nontumor thrombus from HCC vascular invasion. In this cases, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) represents a feasible and safe tool for selected patients as an alternative to classic transabdominal ultrasound-guided fine-needle aspiration[45].

Despite the use of multiple imaging techniques, PVT diagnosis can occur during surgery for liver transplantation. In the retrospective study conducted by Bert *et al*[9], incidental PVT diagnoses during surgery occurred in more than half of the PVT cases in the entire cohort.

The staging of PVT extension is very important to select treatments and to predict the potential response to treatment. However, a comprehensive classification of PVT does not exist. In the setting of liver transplantation, Yerdel’s classification[46] divided PVT into four categories based on the degree of main portal vein obstruction and proximal and distal SMV extension. Each stage correlates with a different portal reconstruction approach, and for stages 2-4, with a lower graft survival. In 2016, Sarin *et al*[37] proposed a new anatomico-functional classification of PVT in cirrhosis, which considers the site and extension of the thrombus, obstruction degree, duration and presentation, and functional relevance of the thrombosis; the aim of this classification is to allow for standardization in future research in this field.

***Natural history and prognosis***

The evolution of untreated PVT is still unclear. Three possible scenarios exist: spontaneous resolution, stabilization, or progression of the thrombus. Data regarding the occurrence of these possibilities are highly variable[22]. Spontaneous resolution or stabilization of the thrombus is the most frequent evolution of PVT and occurs in 45% to 70% of cases[41]. Currently, data on the predictive factors for PVT progression are still lacking. Evidence suggests that the degree of occlusion and extension of the PVT do not correlate with the evolution of thrombosis[47].

Regarding prognosis, PVT seems to be related to a worse prognosis and to negatively influence the decompensation of cirrhosis and long-term survival[48]. Amitrano *et al*[27] showed that PVT is associated with increased overall mortality risk in cirrhosis. The same result was described in more recent studies, which reported that PVT is associated not only with an increased mortality risk[5,49] but also with a major incidence of ascites[49] and major variceal bleeding risks[5]. It is still unclear whether PVT is the cause or the consequence of liver deterioration, and the data are controversial because PVT is clearly associated with more severe portal hypertension and advanced cirrhosis[3].

Conversely, in compensated cirrhosis, the development of PVT is independent of liver disease progression and is not related to decompensation or lower OLT-free survival[50]. These findings might be explained by the fact that the population considered in these studies included a majority of patients with Child-Pugh A, who have fewer risk factors for PVT and a reduced mortality rate than patients with advanced cirrhosis.

Regarding patients who are candidates for orthotopic liver transplantation (OLT), PVT can be detected at the time of listing for liver transplantation or can be diagnosed while patients are on the waiting list. The presence of PVT at the time of listing is associated with worse posttransplant survival[51] and with graft failure after OLT[52].

Although PVT is not a major contraindication for liver transplantation, the presence of a thrombus can reduce surgical feasibility, which is associated with a poor prognosis when nonphysiological reconstruction is performed[53,54]. When end-to-end anastomosis is performed, the survival rate at 1 and 5 years is similar between patients with or without PVT[55]. Conversely, the risk of portal vein rethrombosis, gastrointestinal bleeding and small bowel obstruction is higher when nonphysiological anastomosis is performed[56].

PVT is also associated with a prolonged duration of transplantation surgery (especially when incidentally discovered at the time of surgery), prolonged hospitalization after surgery, and lower 1-year survival, which is independent of the time of detection[9]. The negative impact of PVT on post-OLT survival was documented by a recent meta-analysis, which reported significantly higher 30-day and 1-year mortality in patients with pre-OLT complete PVT than in those with partial PVT or without PVT[57].

The presence of PVT before transplantation is a risk factor for PVT recurrence after liver transplantation[7]. The onset of PVT after liver transplantation is associated with reduced graft and patient survival[58].

**ANTICOAGULANT THERAPY IN PVT WITH CIRRHOSIS**

Anticoagulant agents are the mainstay of therapy in many cases of thromboembolism, such as for the treatment of lower limb venous thrombosis, pulmonary embolism, or stroke prevention in atrial fibrillation.

The role of anticoagulants in cirrhotic patients with portal vein thrombosis is still unclear, especially in chronic asymptomatic PVT and in nonliver transplant candidates. Current guidelines do not propose definitive evidence-based treatment strategies for cirrhotic patients affected by portal vein thrombosis. The American Association for the Study of Liver Diseases (AASLD) suggests that the indication for treatment, anticoagulant type and duration of therapy should be considered on a case-by-case basis[59]. The European Association for the Study of the Liver (EASL) recommends starting anticoagulation with low-molecular-weight heparin (LMWH) in the absence of major contraindications for anticoagulant therapy, switching to vitamin K antagonist (VKA) treatment for at least 6 mo and ensuring that there is prior adequate prophylaxis for gastrointestinal bleeding. No indications were provided for the use of direct oral anticoagulants in this setting[2,59].

The classic anticoagulants commonly used in PVT in cirrhotic patients are LMWH and VKAs, which each has advantages and limitations. LMWH does not require monitoring and has an effect for a limited time. However, subcutaneous injection may reduce compliance, and low antithrombin III levels in cirrhotic patients may compromise the LMWH mechanism of action.

VKAs are usually used for long-term anticoagulation. Their advantages are oral administration and reversibility with vitamin K supplementation. Conversely, VKAs require INR monitoring (which is altered in patients with cirrhosis and probably does not reflect the real hemostatic status) and induce a decrease in anticoagulant proteins C and S, which are already reduced in cirrhotic patients. Fondaparinux, an indirect factor X-activated inhibitor, seems to be effective and safe in advanced cirrhosis, but very little evidence is available[60].

***Efficacy and safety of classic anticoagulants in PVT with cirrhosis***

A body of evidence suggests that anticoagulant treatment of PVT in cirrhosis is effective and safe. In a recent meta-analysis that included 1696 cirrhotic patients with PVT, anticoagulation therapy was significantly associated with portal vein recanalization, a decrease in PVT progression, and an improvement in survival, especially when treatment was started early[61]. According to these results, other recent systematic reviews and meta-analyses reported a pooled response rate to anticoagulation therapy that was considerably higher than that of the control group (66.7% *vs* 26%)[62].

Recanalization of the portal vein in patients treated with anticoagulants is associated with decreased portal hypertension and related complications, with higher OLT-free survival[63].

Instead, the discontinuation of therapy in patients with previous PVT, which is itself considered a risk factor for recurrence[47], is associated with a high PVT recurrence risk[64] (rethrombosis rate of 46.7%) after stopping anticoagulation[61]. Therefore, the duration of anticoagulation after portal vein recanalization is controversial.

Regarding safety, anticoagulant therapy in cirrhotic PVT is not associated with a significant increase in bleeding risk compared with that in untreated cirrhotic patients[62-64].

Regarding the incidence of bleeding, Mohan *et al*[62] reported a pooled rate of bleeding that was similar in patients treated with anticoagulant and the corresponding controls (7.8% *vs* 15.4%). Upper gastrointestinal bleeding in patients with cirrhosis on anticoagulation has the same severity and mortality as in patients with cirrhosis without anticoagulation treatment[65]. In support of these findings, Wang *et al*[61] demonstrated that anticoagulation did not influence overall bleeding and is, therefore, not a predictive factor for bleeding events.

In cirrhotic patients who are candidates for liver transplantation and are affected by PVT, the goal of anticoagulant therapy is to prevent PVT progression and to promote portal and superior mesenteric vein recanalization, allowing end-to-end anastomosis, which is associated with better outcomes. Available guidelines support the use of anticoagulant treatment in cirrhotic patients with PVT who are candidates for transplantation[2,59]; a recent study demonstrated a trend toward recanalization and a beneficial trend toward 1-year survival in cirrhotic patients with PVT awaiting LT who were treated with anticoagulant therapy[9]. No consensus exists regarding anticoagulation therapy after LT. A short course of anticoagulant therapy should be administered to reduce the risk of rethrombosis, while prolonged therapy should be recommended when nonphysiological reconstruction of portal anastomosis is performed[66].

As Ponziani *et al*[39] suggested, the best recommendation for the future is to avoid PVT-related complications by identifying patients at a high risk for PVT and introducing prevention strategies and adequate prophylaxis. In this field, only one prospective study demonstrated that prophylactic anticoagulation with LMWH in Child-Pugh B or C was associated with decreased hepatic decompensation and better survival[67]. Gaballa *et al*[68] proposed a scoring system to predict and stratify the risk of PVT in cirrhosis. This score, called the PVT risk index (PVT-RI), was developed to predict the incidence of PVT in liver transplant candidates and considers five variables associated with a higher PVT risk: Age, African American descent, the Model for End-Stage Liver Disease (MELD) score, moderate/severe ascites and nonalcoholic steatohepatitis (NASH). A PVT-RI < 2.6 has a negative predictive value of 94% and could be used to establish the time of ultrasound surveillance. A PVT-RI > 4.6, with a positive predictive value of 85%, could identify a high-risk population that would benefit from anticoagulant prophylaxis[68].

In this review, neoplastic PVT, which occurs as a complication of HCC, was not considered since anticoagulation therapy is not recommended. Instead, the treatment of choice for neoplastic PVT includes surgical resection, radiotherapy, TACE and systemic therapy[69]. Nonneoplastic PVT occurs in approximately a quarter of patients with HCC, but no evidence exists about the role of anticoagulants in this setting[47].

***Direct oral anticoagulants***

In the last ten years, direct oral anticoagulants (DOACs) have been increasingly prescribed to prevent stroke in nonvalvular atrial fibrillation and to treat thromboembolic disorders, such as venous thromboembolism and pulmonary embolism, after their approval[69,70].

In regard to pharmacodynamic properties, DOACs can be divided into two categories: Factor X-activated inhibitors, such as rivaroxaban, apixaban and edoxaban, and factor II-activated inhibitors, such as dabigatran. Compared with classic anticoagulant molecules (LWMHs and VKAs), among the advantages of DOACs are their oral administration in fixed doses, poor interaction with other drugs and predictable pharmacokinetic profiles and anticoagulant effects; therefore, they do not need laboratory monitoring. Rivaroxaban is metabolized by cytochrome P450 without forming active metabolites and is mostly eliminated by renal excretion. Apixaban and edoxaban are metabolized by cytochrome P3A4 without forming active metabolites. Apixaban is eliminated by renal excretion (approximately 25% of the absorbed dose) and hepatic metabolism but mainly by intestinal excretion (approximately 55%). Edoxaban is eliminated by the hepatobiliary (approximately 65%) and renal (approximately 35%) systems. Rivaroxaban, apixaban and edoxaban act independently of endogenous antithrombin. This could be useful in cirrhosis where antithrombin is reduced. Dabigatran is an oral prodrug metabolized by esterase in various organs, including the liver, but not by hepatic cytochrome, and approximately 80% of it is eliminated by renal excretion[71]. Renal impairment is the main factor that influences the pharmacokinetics of DOACs. Regarding hepatic function, clinical recommendations or contraindications are based on a small amount of evidence because cirrhotic patients have usually been excluded from trials of these drugs[47]. Experience from the long-term use of DOACs in this setting is still limited. All DOACs can be used in patients with mild hepatic dysfunction (Child-Pugh A) without a significant bleeding risk. In patients with moderate hepatic dysfunction (Child-Pugh B), dabigatran, apixaban and edoxaban can be used with caution, while rivaroxaban should not be used because of increased plasma concentrations and pharmacodynamic effects[72]. In severe hepatic dysfunction (Child-Pugh C), DOACs are not recommended[73].

Regarding hepatotoxicity, a recent systematic literature review reported two new cases of hepatocellular liver injury in patients treated with rivaroxaban[74], in addition to a case report by Liakoni *et al*[75], who described his experience with ximelagatran, which was withdrawn two years after approval because of severe hepatotoxicity[76]. However, the real hepatotoxic effect of new oral anticoagulants is still unknown. All new oral anticoagulants can lead to hepatotoxicity with an idiosyncratic mechanism, but this adverse event is very rare[77]. A recent meta-analysis considering patients treated with DOACs demonstrated that the incidence of drug-induced liver injury (DILI) was insignificant when the data of each drug were individually analysed[78]. A prospective study showed that dabigatran, rivaroxaban, apixaban and edoxaban are associated with a lower incidence of liver injury than warfarin, and among these, dabigatran seems to be the safest[79], probably due to its pharmacokinetic characteristics.

When the EASL published guidelines about PVT treatment in cirrhosis in 2016, no specific indications were described for the use of DOACs, and they emphasized the need for randomized trials to assess the efficacy and safety of DOACs in cirrhosis[2]. These recommendations have been confirmed by the most recent AASLD guidelines. The lack of evidence is the result of patients with signs of liver disease being excluded from clinical trials with DOACs[59].

***Safety of DOACs in cirrhosis: current evidence***

Evidence regarding the safety of DOACs in cirrhotic patients affected by atrial fibrillation or venous thromboembolism suggests that DOACs may be safe in patients with mild to moderate chronic liver disease, with rates of bleeding similar to those of traditional anticoagulants[80]. In a recent publication, Violi *et al*[47] concluded that DOACs may be considered for the treatment of deep venous thrombosis or for prophylaxis in patients with atrial fibrillation when cirrhotic patients are not eligible for VKAs.

In a more recent extended systematic review and meta-analysis, Menichelli *et al*[81] investigated the safety of DOACs compared to VKAs in patients with advanced liver disease who received anticoagulants for atrial fibrillation or deep vein thrombosis. The primary endpoints were any bleeding, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage. Considering more than forty thousand patients, the authors concluded that treatment with DOACs compared to VKAs is associated with a lower risk of major bleeding, intracranial hemorrhage, and all types of bleeding (pooled hazard ratios 0.39, 0.48 and 0.73, respectively), with no difference in gastrointestinal bleeding. Subsequently, the subanalysis of only cirrhotic patients showed no difference in safety outcomes between the DOAC and VKA groups[81]. In accordance with this study, a retrospective longitudinal analysis conducted by Serper *et al*[82] also demonstrated that DOACs were associated with a significantly lower incidence of bleeding than VKAs in a cohort of cirrhotic patients with atrial fibrillation. Moreover, both anticoagulant classes have been proven to be capable of reducing all-cause mortality and the incidence rate of hepatic decompensation when compared with any anticoagulant therapy.

Regarding the safety of DOACs in cirrhotic patients with PVT, one of the first studies was conducted by De Gottardi *et al*[83], who compared the rate of bleeding in cirrhotic patients with that in noncirrhotic controls. In this study, 36 patients affected by mild to moderate liver cirrhosis treated with DOACs for a mean of 9.6 mo were included. Major or minor bleeding was reported in 5 cirrhotic patients (13.9%); however, in 58 noncirrhotic patients treated with DOACs, minor and major bleeding was reported in 9 (15.9%) patients.

Regarding the safety of DOACs compared to traditional anticoagulants, Intagliata *et al*[84] reported a comparable bleeding rate in patients affected by mild to moderate cirrhosis. In this study, the rate of bleeding was analyzed in 20 cirrhotic patients prophylactically or therapeutically treated with rivaroxaban or apixaban compared with 19 cirrhotic patients treated with traditional anticoagulants. The indications for anticoagulant therapy were atrial fibrillation or VTE, including PVT. The total bleeding and major bleeding rates were not significantly different between the two groups[84]. Similarly, Hum *et al*[85] investigated the difference in bleeding events between DOACs and traditional anticoagulants in cirrhotic patients. Twenty-seven patients treated with rivaroxaban or apixaban and 18 patients treated with warfarin or LMWH affected by atrial fibrillation and venous thromboembolism, including PVT, were included. Total bleeding was similar in the two groups: 10 events in the traditional group and 8 in the DOAC group (*P =* 0.12). Major bleeding was significantly higher in the traditional group than in the DOAC group (5 *vs* 1, *P =* 0.03).

Table 1 summarizes the evidence about DOAC safety in cirrhosis. The main limitation in assessing DOAC safety in patients with cirrhosis is the lack of uniformity in outcome definitions. In the studies examined, different bleeding definitions were used. To address this lack of uniformity, Nisly *et al*[86] conducted a systematic review and meta-analysis considering only studies in which the primary safety outcome was major bleeding according to the definition of the International Society on Thrombosis and Haemostasis (ISTH). In these studies, pooled analysis demonstrated the absence of a statistically significant difference between DOACs and traditional anticoagulants for ISTH major bleeding in cirrhotic patients treated for stroke prevention or venous thromboembolism[86].

***Efficacy of DOACs in PVT: Current evidence***

Studies regarding the efficacy of DOACs to treat PVT in cirrhosis are very limited (Table 2). Ai *et al*[87] studied the efficacy of rivaroxaban and dabigatran[87]. In this prospective study, 80 patients with chronic PVT were enrolled and divided into two groups: 40 patients were treated for 6 mo with DOACs, 26 patients with rivaroxaban 20 mg once daily, 14 patients with dabigatran 150 mg twice daily, and 40 control patients were not treated with anticoagulant therapy. At 0, 3 and 6 mo, patients were tested with ultrasound and pulsed Doppler to establish the portal blood flow rate and CT portal angiography to examine thrombus extension. Regarding efficacy, in treated patients, a significant response in terms of complete/partial recanalization and improved portal blood flow velocity compared with the control group was demonstrated, which was superior at 6 mo than at 3 mo. The majority of recanalized patients were Child-Pugh A, and none of them were Child-Pugh C. Regarding safety, no significantly different bleeding rates in the treated *vs* the control group were shown. In this study, patients with moderate to severe esophageal varices and platelet counts below 50 × 109/L were excluded.

Comparing DOACs with classic anticoagulants, Hanafy *et al*[88] designed a randomized, controlled, interventional study in which they compared the efficacy and safety of rivaroxaban with warfarin to treat acute portal thrombosis in HCV-related cirrhosis. Eighty patients were enrolled. After 3 days of enoxaparin 1 mg/kg every 12 h, forty patients continued therapy with rivaroxaban 10 mg twice daily; instead, controls were treated with warfarin at variable dosages to maintain the international normalized ratio (INR) between 2 and 2.5. Regarding efficacy, the primary outcome was partial or complete PVT recanalization; the secondary outcome was the absence of recurrence after the end of therapy. Regarding safety, the main outcome was major bleeding. The results showed that rivaroxaban was more effective than warfarin in terms of complete or partial recanalization, time to recanalization, recurrence of PVT and safety, with a significantly lower risk of major bleeding[88].

In a retrospective analysis, Nagaoki *et al*[89] evaluated the efficacy and safety of edoxaban compared with warfarin to treat PVT in cirrhotic patients after 2 wk of danaparoid sodium. Twenty patients were enrolled in the edoxaban group and received 60 mg or 30 mg once daily depending on renal function, body weight and concomitant drug administration. Thirty patients were enrolled in the control group treated with warfarin, and the INR target was 1.5-2. The duration of the study was 6 mo. Efficacy was evaluated in terms of PVT volume and PVT reduction rate at 2 wk and 1, 3 and 6 mo, as assessed with dynamic CT. Safety was evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Additionally, in this study, the findings demonstrated the effectiveness of DOACs compared to warfarin, showing a significant reduction in thrombus volume after 6 mo of treatment and a higher prevalence of complete response. Regarding safety, there were no significant dissimilarities between the two groups[89].

**AREAS OF UNCERTAINTY**

Although evidence has shown the noninferiority of DOACs compared with traditional anticoagulant therapy, the studies examined varied in design, and no universal outcome definition was used. Furthermore, in these studies, no uniformity in dosage strategy, treatment duration, clear predictor efficacy or evidence on the ideal time of initiation and duration of anticoagulant therapy were described. This poses a challenge for establishing the real effect and benefit of anticoagulant therapy with DOACs in terms of portal recanalization.

Regarding safety, the definition of bleeding events varied between studies. However, the safety of DOACs appears comparable or superior to that of classic anticoagulants. In addition, a major limitation, which is shared in these studies, regards the characteristics of the patients included. Most of the patients considered were affected by compensated cirrhosis. Insufficient data are reported about the safety and efficacy of DOACs in patients affected by advanced liver cirrhosis.

No evidence exists about the role of prophylactic anticoagulant therapy. Villa *et al*[67] demonstrated that prophylactic anticoagulant therapy with LMWH has some beneficial effects on the deterioration of liver function and survival. Most likely, DOACs may contribute to reducing liver damage, especially in early cirrhosis stages, and superior drug tolerance makes them suitable for wider use. The pharmacodynamic and pharmacokinetic characteristics of DOACs could be an important tool for portal vein thrombosis prophylaxis, but patients who would benefit most from this therapy have not yet been identified. A defined stratification of the portal vein thrombosis risk is still lacking. There is a need to validate scores to establish PVT risk and subsequent prophylactic anticoagulant therapy.

In the setting of liver transplantation, anticoagulant therapy with DOACs in patients with PVT on a waiting list is a potential option to allow recanalization of the portal vein and to allow physiological reconstruction of vessels. The major advantage for patients who are waiting for liver transplantation is the possibility of counteracting the anticoagulant effect with reversal agents at any time, such as idarucizumab for dabigatran or andexanet alfa for rivaroxaban. The main limitations are the high cost, availability, and lack of evidence about their use in cirrhotic patients, especially with decompensated disease.

**CONCLUSION**

This review emphasizes that DOACs could represent a valid alternative to the currently poorly defined standard of care for portal vein thrombosis. However, we show that the lack of evidence and inhomogeneity of studies regarding outcome definitions to evaluate efficacy and safety poses challenges to clinical trial design to evaluate DOACs and, as consequence, its use in clinical practice.

As shown here, in cirrhotic patients with mild hepatic function impairment, the safety and efficacy of new oral anticoagulants seems to be noninferior compared with classic anticoagulants, especially in patients with a low bleeding risk (platelet count >100,000/mm3 and no high-risk esophageal varices). No significant differences between dabigatran, rivaroxaban, and edoxaban have been observed, while data on apixaban for treating portal vein thrombosis in cirrhotic patients are limited[90]. In patients with moderate liver dysfunction, anticoagulant drugs need to be selected with caution, especially those metabolized by liver cytochromes. Considering this, molecules with a predominantly renal metabolism might be preferred in more advanced liver disease. In patients awaiting liver transplantation, dabigatran may be promising in preventing thrombosis progression because of the low rate of hepatotoxicity, predominant renal metabolism and reversibility by idarucizumab in perioperative management. Well-designed randomized controlled trials are needed to further evaluate the safety and efficacy of DOACs to treat PVT in cirrhotic patients, especially in patients listed in the OLT setting.

**ACKNOWLEDGEMENTS**

We would like to thank Lohmeyer FM, PhD, Fondazione Policlinico Universitario A. Gemelli IRCCS, for her help revising our manuscript.

**REFERENCES**

1 **Intagliata NM**, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. *Gastroenterology* 2019; **156**: 1582-1599.e1 [PMID: 30771355 DOI: 10.1053/j.gastro.2019.01.265]

2 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.**. EASL Clinical Practice Guidelines: Vascular diseases of the liver. *J Hepatol* 2016; **64**: 179-202 [PMID: 26516032 DOI: 10.1016/j.jhep.2015.07.040]

3 **Nery F**, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet JC, Valla DC; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. *Hepatology* 2015; **61**: 660-667 [PMID: 25284616 DOI: 10.1002/hep.27546]

4 **Violi F**, Corazza GR, Caldwell SH, Perticone F, Gatta A, Angelico M, Farcomeni A, Masotti M, Napoleone L, Vestri A, Raparelli V, Basili S; PRO-LIVER Collaborators. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. *Intern Emerg Med* 2016; **11**: 1059-1066 [PMID: 27026379 DOI: 10.1007/s11739-016-1416-8]

5 **Zhang Y**, Xu BY, Wang XB, Zheng X, Huang Y, Chen J, Meng ZJ, Gao YH, Qian ZP, Liu F, Lu XB, Shi Y, Shang J, Li H, Wang SY, Yin S, Sun SN, Hou YX, Xiong Y, Chen J, Li BL, Lei Q, Gao N, Ji LJ, Li J, Jie FR, Zhao RH, Liu JP, Lin TF, Chen LY, Tan WT, Zhang Q, Zou CC, Huang ZB, Jiang XH, Luo S, Liu CY, Zhang YY, Li T, Ren HT, Wang SJ, Deng GH, Xiong SE, Liu XX, Wang C, Yuan W, Gu WY, Qiao L, Wang TY, Wu DD, Dong FC, Li H, Hua J. Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation. *Clin Gastroenterol Hepatol* 2020; **18**: 2564-2572.e1 [PMID: 32109631 DOI: 10.1016/j.cgh.2020.02.037]

6 **Cagin YF**, Atayan Y, Erdogan MA, Dagtekin F, Colak C. Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients. *Hepatobiliary Pancreat Dis Int* 2016; **15**: 499-503 [PMID: 27733319 DOI: 10.1016/S1499-3872(16)60092-9]

7 **Ponziani FR**, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. *Transplant Rev (Orlando)* 2014; **28**: 92-101 [PMID: 24582320 DOI: 10.1016/j.trre.2014.01.003]

8 **Francoz C**, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. *Gut* 2005; **54**: 691-697 [PMID: 15831918 DOI: 10.1136/gut.2004.042796]

9 **Bert J**, Geerts A, Vanlander A, Abreu de Carvalho L, Degroote H, Berrevoet F, Rogiers X, van Vlierberghe H, Verhelst X. Up to 50% of portal vein thrombosis remains undiagnosed until liver transplantation. *Clin Transplant* 2020; **34**: e14107 [PMID: 33030231 DOI: 10.1111/ctr.14107]

10 **Plessier A**, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D; European Network for Vascular Disorders of the Liver (EN-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. *Hepatology* 2010; **51**: 210-218 [PMID: 19821530 DOI: 10.1002/hep.23259]

11 **Tripodi A,** Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. *J Hepatol* 2013; **59**: 265-270 [PMID: 23583273 DOI: 10.1016/j.jhep.2013.03.036]

12 **Tripodi A**, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. *J Hepatol* 2013; **59**: 265-270 [PMID: 23583273 DOI: 10.1111/jth.14011]

13 **Moore AH**. Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options. *Clin Liver Dis (Hoboken)* 2019; **14**: 183-186 [PMID: 31879561 DOI: 10.1002/cld.860]

14 **Zermatten MG**, Fraga M, Moradpour D, Bertaggia Calderara D, Aliotta A, Stirnimann G, De Gottardi A, Alberio L. Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. *Hepatology* 2020; **71**: 2135-2148 [PMID: 32090357 DOI: 10.1002/hep.31201]

15 **Martinez J**, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. *Blood* 1983; **61**: 1196-1202 [PMID: 6839020 DOI: 10.1182/blood.V61.6.1196.1196]

16 **Ahmad S,** Hunt BJ. Coagulopathy of Liver Disease. In: Gonzalez E, Moore HB, Moore EE, editors. Trauma Induced Coagulopathy. Cham: Springer International Publishing, 2016: 471-482 [DOI: 10.1007/978-3-319-28308-1\_29]

17 **Tripodi A**, Mannucci PM. The coagulopathy of chronic liver disease. *N Engl J Med* 2011; **365**: 147-156 [PMID: 21751907 DOI: 10.1056/NEJMra1011170]

18 **Kalambokis GN**, Oikonomou A, Christou L, Kolaitis NI, Tsianos EV, Christodoulou D, Baltayiannis G. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. *J Hepatol* 2016; **65**: 921-928 [PMID: 27297911 DOI: 10.1016/j.jhep.2016.06.002]

19 **Lebreton A**, Sinegre T, Lecompte T, Talon L, Abergel A, Lisman T. Thrombin Generation and Cirrhosis: State of the Art and Perspectives. *Semin Thromb Hemost* 2020; **46**: 693-703 [PMID: 32820480 DOI: 10.1055/s-0040-1715102]

20 **Zocco MA**, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. *J Hepatol* 2009; **51**: 682-689 [PMID: 19464747 DOI: 10.1016/j.jhep.2009.03.013]

21 **Stine JG**, Argo CK, Pelletier SJ, Maluf DG, Caldwell SH, Northup PG. Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. *World J Hepatol* 2017; **9**: 139-146 [PMID: 28217250 DOI: 10.4254/wjh.v9.i3.139]

22 **Nicoară-Farcău O**, Soy G, Magaz M, Baiges A, Turon F, Garcia-Criado A, Barrufet M, Burrel M, Hernández-Gea V, García-Pagán JC. New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis. *Semin Thromb Hemost* 2020; **46**: 673-681 [PMID: 32820481 DOI: 10.1055/s-0040-1715473]

23 **Garcia-Tsao G**, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. *N Engl J Med* 2010; **362**: 823-832 [PMID: 20200386 DOI: 10.1056/NEJMra0901512]

24 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.**; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018; **69**: 406-460 [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024]

25 **Xu X**, Guo X, De Stefano V, Silva-Junior G, Goyal H, Bai Z, Zhao Q, Qi X. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. *Hepatol Int* 2019; **13**: 468-481 [PMID: 31175581 DOI: 10.1007/s12072-019-09951-6]

26 **Maruyama H**, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. *Am J Gastroenterol* 2013; **108**: 568-574 [PMID: 23381015 DOI: 10.1038/ajg.2012.452]

27 **Amitrano L**, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, Balzano A. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. *J Hepatol* 2004; **40**: 736-741 [PMID: 15094219 DOI: 10.1016/j.jhep.2004.01.001]

28 **Amitrano L**, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, Marmo R, Ames PR, Balzano A. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. *Hepatology* 2000; **31**: 345-348 [PMID: 10655256 DOI: 10.1002/hep.510310213]

29 **Kirkeby MH**, Larsen JB, Grønbaek H, Hvas AM. Thrombophilia testing in patients with portal vein thrombosis. *Scand J Clin Lab Invest* 2020; **80**: 694-698 [PMID: 33026843 DOI: 10.1080/00365513.2020.1827289]

30 **Ma SD**, Wang J, Bezinover D, Kadry Z, Northup PG, Stine JG. Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. *Res Pract Thromb Haemost* 2019; **3**: 658-667 [PMID: 31624785 DOI: 10.1002/rth2.12253]

31 **Rodriguez-Castro KI**, Vitale A, Fadin M, Shalaby S, Zerbinati P, Sartori MT, Landi S, Pettinari I, Piscaglia F, Han G, Burra P, Simioni P, Senzolo M. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. *Eur J Gastroenterol Hepatol* 2019; **31**: 34-42 [PMID: 30188408 DOI: 10.1097/MEG.0000000000001237]

32 **Fortea JI**, Carrera IG, Puente Á, Cuadrado A, Huelin P, Tato CÁ, Fernández PÁ, Montes MDRP, Céspedes JN, López AB, Sanchez FJG, Hoyos ML, Crespo J, Fábrega E. Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders. *J Clin Med* 2020; **9** [PMID: 32878264 DOI: 10.3390/jcm9092822]

33 **Shalaby S**, Simioni P, Campello E, Spiezia L, Gavasso S, Bizzaro D, Cardin R, D'Amico F, Gringeri E, Cillo U, Barbiero G, Battistel M, Zanetto A, Ruzzarin A, Burra P, Senzolo M. Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. *Thromb Haemost* 2020; **120**: 1173-1181 [PMID: 32604425 DOI: 10.1055/s-0040-1713169]

34 **Praktiknjo M**, Trebicka J, Carnevale R, Pastori D, Queck A, Ettorre E, Violi F. Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. *Clin Transl Gastroenterol* 2020; **11**: e00123 [PMID: 32032127 DOI: 10.14309/ctg.0000000000000123]

35 **Carnevale R**, Raparelli V, Nocella C, Bartimoccia S, Novo M, Severino A, De Falco E, Cammisotto V, Pasquale C, Crescioli C, Scavalli AS, Riggio O, Basili S, Violi F. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. *J Hepatol* 2017; **67**: 950-956 [PMID: 28716745 DOI: 10.1016/j.jhep.2017.07.002]

36 **Fan X**, Huang X, Hershman M, Zheng X, Jiang C, Yue B, Weisberg I. Portal vein thrombosis prevalence and mortality among alcoholic cirrhosis in a nationwide inpatient cohort. *Eur J Gastroenterol Hepatol* 2020; **32**: 1160-1167 [PMID: 31834054 DOI: 10.1097/MEG.0000000000001624]

37 **Sarin SK**, Philips CA, Kamath PS, Choudhury A, Maruyama H, Nery FG, Valla DC. Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. *Gastroenterology* 2016; **151**: 574-577.e3 [PMID: 27575821 DOI: 10.1053/j.gastro.2016.08.033]

38 **Primignani M**. Portal vein thrombosis, revisited. *Dig Liver Dis* 2010; **42**: 163-170 [PMID: 19766546 DOI: 10.1016/j.dld.2009.08.003]

39 **Ponziani FR**, Zocco MA, Campanale C, Rinninella E, Tortora A, Di Maurizio L, Bombardieri G, De Cristofaro R, De Gaetano AM, Landolfi R, Gasbarrini A. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. *World J Gastroenterol* 2010; **16**: 143-155 [PMID: 20066733 DOI: 10.3748/wjg.v16.i2.143]

40 **Alzubaidi S**, Patel I, Saini A, Knuttinen G, Naidu S, Kriegshuaser S, Albadawi H, Oklu R. Current concepts in portal vein thrombosis: etiology, clinical presentation and management. *Abdom Radiol (NY)* 2019; **44**: 3453-3462 [PMID: 31407054 DOI: 10.1007/s00261-019-02174-1]

41 **Rugivarodom M**, Charatcharoenwitthaya P. Nontumoral Portal Vein Thrombosis: A Challenging Consequence of Liver Cirrhosis. *J Clin Transl Hepatol* 2020; **8**: 432-444 [PMID: 33447527 DOI: 10.14218/JCTH.2020.00067]

42 **Margini C**, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. *Dig Liver Dis* 2017; **49**: 113-120 [PMID: 27965037 DOI: 10.1016/j.dld.2016.11.013]

43 **Sherman CB**, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. *Liver Transpl* 2019; **25**: 207-216 [PMID: 30246323 DOI: 10.1002/Lt.25345]

44 **Chen J**, Zhu J, Zhang C, Song Y, Huang P. Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis. *Eur Radiol* 2020; **30**: 2871-2880 [PMID: 32020403 DOI: 10.1007/s00330-019-06649-z]

45 **Gimeno Garcia AZ**, Aparicio JR, Barturen A, Moreno M, Nicolas-Perez D, Quintero E. Short article: Endoscopic ultrasound-guided fine-needle aspiration of portal vein thrombosis in patients with chronic liver disease and suspicion of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2018; **30**: 418-423 [PMID: 29420366 DOI: 10.1097/MEG.0000000000001094]

46 **Yerdel MA**, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J, Mayer D, McMaster P, Pirenne J. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. *Transplantation* 2000; **69**: 1873-1881 [PMID: 10830225 DOI: 10.1097/00007890-200005150-00023]

47 **Violi F**, Loffredo L, Pastori D. Anticoagulation in patients with advanced liver disease: an open issue. *Intern Emerg Med* 2021; **16**: 61-71 [PMID: 33073317 DOI: 10.1007/s11739-020-02526-6]

48 **Qi X**, Dai J, Yang M, Ren W, Jia J, Guo X. Association between Portal Vein Thrombosis and Survival in Non-Liver-Transplant Patients with Liver Cirrhosis: A Systematic Review of the Literature. *Gastroenterol Res Pract* 2015; **2015**: 480842 [PMID: 25810714 DOI: 10.1155/2015/480842]

49 **Stine JG**, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, Northup PG. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. *World J Hepatol* 2015; **7**: 2774-2780 [PMID: 26644821 DOI: 10.4254/wjh.v7.i27.2774]

50 **Noronha Ferreira C**, Reis D, Cortez-Pinto H, Tato Marinho R, Gonçalves A, Palma S, Leite I, Rodrigues T, Pedro AJ, Alexandrino P, Serejo F, Sobral Dias M, Ferreira P, Vasconcelos M, Damião F, Xavier Brito L, Baldaia C, Fatela N, Ramalho F, Velosa J. Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis. *Dig Dis Sci* 2019; **64**: 2671-2683 [PMID: 30852769 DOI: 10.1007/s10620-019-05572-z]

51 **Montenovo M**, Rahnemai-Azar A, Reyes J, Perkins J. Clinical Impact and Risk Factors of Portal Vein Thrombosis for Patients on Wait List for Liver Transplant. *Exp Clin Transplant* 2018; **16**: 166-171 [PMID: 28621635 DOI: 10.6002/ect.2016.0277]

52 **Ghabril M**, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients. *Transplantation* 2016; **100**: 126-133 [PMID: 26050013 DOI: 10.1097/TP.0000000000000785]

53 **Turon F**, Hernández-Gea V, García-Pagán JC. Portal vein thrombosis: yes or no on anticoagulation therapy. *Curr Opin Organ Transplant* 2018; **23**: 250-256 [PMID: 29432256 DOI: 10.1097/MOT.0000000000000506]

54 **Chen H**, Turon F, Hernández-Gea V, Fuster J, Garcia-Criado A, Barrufet M, Darnell A, Fondevila C, Garcia-Valdecasas JC, Garcia-Pagán JC. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. *Liver Transpl* 2016; **22**: 352-365 [PMID: 26684272 DOI: 10.1002/Lt.24387]

55 **Francoz C**, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. *J Hepatol* 2012; **57**: 203-212 [PMID: 22446690 DOI: 10.1016/j.jhep.2011.12.034]

56 **Hibi T**, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, Ruiz P, Tzakis AG. When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. *Ann Surg* 2014; **259**: 760-766 [PMID: 24299686 DOI: 10.1097/SLA.0000000000000252]

57 **Zanetto A**, Rodriguez-Kastro KI, Germani G, Ferrarese A, Cillo U, Burra P, Senzolo M. Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis. *Transpl Int* 2018; **31**: 1318-1329 [PMID: 30230053 DOI: 10.1111/tri.13353]

58 **Duffy JP**, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, Busuttil RW. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. *J Am Coll Surg* 2009; **208**: 896-903; discussion 903-5 [PMID: 19476857 DOI: 10.1016/j.jamcollsurg.2008.12.032]

59 **Northup PG**, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2021; **73**: 366-413 [PMID: 33219529 DOI: 10.1002/hep.31646]

60 **Zhang ZH**, Zhang JW, He P, Zhou Y, Sun CY. Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients. *Medicine (Baltimore)* 2017; **96**: e8256 [PMID: 29049216 DOI: 10.1097/MD.0000000000008256]

61 **Wang L**, Guo X, Xu X, De Stefano V, Plessier A, Noronha Ferreira C, Qi X. Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. *Adv Ther* 2021; **38**: 495-520 [PMID: 33155180 DOI: 10.1007/s12325-020-01550-4]

62 **Mohan BP**, Aravamudan VM, Khan SR, Ponnada S, Asokkumar R, Adler DG. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis. *Ann Gastroenterol* 2020; **33**: 521-527 [PMID: 32879600 DOI: 10.20524/aog.2020.0503]

63 **La Mura V**, Braham S, Tosetti G, Branchi F, Bitto N, Moia M, Fracanzani AL, Colombo M, Tripodi A, Primignani M. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. *Clin Gastroenterol Hepatol* 2018; **16**: 1146-1152.e4 [PMID: 29066371 DOI: 10.1016/j.cgh.2017.10.016]

64 **Pettinari I**, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, Sparchez Z, Andreone P, Piscaglia F; BO-LIVES (BOlogna LIVEr vascular Studies). Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. *Am J Gastroenterol* 2019; **114**: 258-266 [PMID: 30538290 DOI: 10.1038/s41395-018-0421-0]

65 **Cerini F**, Gonzalez JM, Torres F, Puente Á, Casas M, Vinaixa C, Berenguer M, Ardevol A, Augustin S, Llop E, Senosiaín M, Villanueva C, de la Peña J, Bañares R, Genescá J, Sopeña J, Albillos A, Bosch J, Hernández-Gea V, Garcia-Pagán JC. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. *Hepatology* 2015; **62**: 575-583 [PMID: 25773591 DOI: 10.1002/hep.27783]

66 **Bhangui P**, Fernandes ESM, Di Benedetto F, Joo DJ, Nadalin S. Current management of portal vein thrombosis in liver transplantation. *Int J Surg* 2020; **82S**: 122-127 [PMID: 32387201 DOI: 10.1016/j.ijsu.2020.04.068]

67 **Villa E**, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. *Gastroenterology* 2012; **143**: 1253-1260.e4 [PMID: 22819864 DOI: 10.1053/j.gastro.2012.07.018]

68 **Gaballa D**, Bezinover D, Kadry Z, Eyster E, Wang M, Northup PG, Stine JG. Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index. *Liver Transpl* 2019; **25**: 1747-1755 [PMID: 31436367 DOI: 10.1002/Lt.25630]

69 **Steffel J**, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J* 2018; **39**: 1330-1393 [PMID: 29562325 DOI: 10.1093/eurheartj/ehy136]

70 **Konstantinides SV**, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J* 2020; **41**: 543-603 [PMID: 31504429 DOI: 10.1093/eurheartj/ehz405]

71 **Harder S**, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. *Eur J Clin Pharmacol* 2013; **69**: 1617-1633 [PMID: 23619611 DOI: 10.1007/s00228-013-1510-z]

72 **Kubitza D**, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. *Br J Clin Pharmacol* 2013; **76**: 89-98 [PMID: 23294275 DOI: 10.1111/bcp.12054]

73 **Graff J**, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. *Clin Pharmacokinet* 2013; **52**: 243-254 [PMID: 23389892 DOI: 10.1007/s40262-013-0034-0]

74 **Licata A**, Puccia F, Lombardo V, Serruto A, Minissale MG, Morreale I, Giannitrapani L, Soresi M, Montalto G, Almasio PL. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. *Eur J Gastroenterol Hepatol* 2018; **30**: 226-232 [PMID: 29120909 DOI: 10.1097/MEG.0000000000001030]

75 **Liakoni E**, Rätz Bravo AE, Terracciano L, Heim M, Krähenbühl S. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. *JAMA Intern Med* 2014; **174**: 1683-1686 [PMID: 25155865 DOI: 10.1001/jamainternmed.2014.3912]

76 **Keisu M**, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. *Handb Exp Pharmacol* 2010: 407-418 [PMID: 20020269 DOI: 10.1007/978-3-642-00663-0\_13]

77 **Liakoni E**, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). *Drug Saf* 2015; **38**: 711-720 [PMID: 26138527 DOI: 10.1007/s40264-015-0317-5]

78 **Caldeira D**, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. *Heart* 2014; **100**: 550-556 [PMID: 24476812 DOI: 10.1136/heartjnl-2013-305288]

79 **Alonso A**, MacLehose RF, Chen LY, Bengtson LG, Chamberlain AM, Norby FL, Lutsey PL. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. *Heart* 2017; **103**: 834-839 [PMID: 28057799 DOI: 10.1136/heartjnl-2016-310586]

80 **Steuber TD**, Howard ML, Nisly SA. Direct Oral Anticoagulants in Chronic Liver Disease. *Ann Pharmacother* 2019; **53**: 1042-1049 [PMID: 30947523 DOI: 10.1177/1060028019841582]

81 **Menichelli D**, Ronca V, Di Rocco A, Pignatelli P, Marco Podda G; CAR. Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis. *Eur J Clin Invest* 2021; **51**: e13397 [PMID: 32895926 DOI: 10.1111/eci.13397]

82 **Serper M**, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. *Hepatology* 2021; **73**: 219-232 [PMID: 32267547 DOI: 10.1002/hep.31264]

83 **De Gottardi A**, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascuès C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, Garcia-Pagan JC; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver Int* 2017; **37**: 694-699 [PMID: 27778440 DOI: 10.1111/Liv.13285]

84 **Intagliata NM**, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. *Dig Dis Sci* 2016; **61**: 1721-1727 [PMID: 26725062 DOI: 10.1007/s10620-015-4012-2]

85 **Hum J**, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. *Eur J Haematol* 2017; **98**: 393-397 [PMID: 28009449 DOI: 10.1111/ejh.12844]

86 **Nisly SA**, Mihm AE, Gillette C, Davis KA, Tillett J. Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. *J Thromb Thrombolysis* 2021; **52**: 817-827 [PMID: 33728575 DOI: 10.1007/s11239-021-02424-4]

87 **Ai MH**, Dong WG, Tan XP, Xu L, Xu C, Zhang Q, Zhang Y, Li J. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. *Eur J Gastroenterol Hepatol* 2020; **32**: 1395-1400 [PMID: 32675774 DOI: 10.1097/MEG.0000000000001846]

88 **Hanafy AS**, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. *Vascul Pharmacol* 2019; **113**: 86-91 [PMID: 29886103 DOI: 10.1016/j.vph.2018.05.002]

89 **Nagaoki Y**, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, Hatooka M, Morio K, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. *Hepatol Res* 2018; **48**: 51-58 [PMID: 28342265 DOI: 10.1111/hepr.12895]

90 **Dibiasi C**, Wiegele M, Gratz J. Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis. *J Clin Anesth* 2019; **56**: 41-42 [PMID: 30684925 DOI: 10.1016/j.jclinane.2019.01.020]

91 **Goriacko P**, Veltri KT. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. *Eur J Haematol* 2018; **100**: 488-493 [PMID: 29444357 DOI: 10.1111/ejh.13045]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 30, 2021

**First decision:** July 27, 2021

**Article in press:** April 3, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Voulgaris T, Greece **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Table 1 Safety of direct oral anticoagulants in cirrhosis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Drug administrated (n of patients)** | **Child-Pugh score at baseline** | **Indication for anticoagulant therapy** | **Definition of events** | **Events in cases *vs* control** |
| Ai *et al*[87] | Rivaroxaban 20 mg once daily (26 pts) | Mean 7.2 | PVT | No definition of events | 3 *vs* 1 (*P =* 0.616); 1 hematuria in dabigatran; 1 hemoptysis in rivaroxaban; 1 melena in rivaroxaban |
| Dabigatran 150 mg twice daily (14 pts) |
| No anticoagulant (40 pts) | Mean 7.4 |
| Hanafy *et al*[88] | Rivaroxaban 10 mg twice daily (40 pts) | Mean 6.4 | PVT | Major bleeding | 0 *vs* 17 (*P =* 0.001) |
| Warfarin; (40 pts) | Mean 6.2 | Death bleeding related | 0 *vs* 8 (*P =* 0.001) |
| Nagaoki *et al*[89] | Edoxaban 60 mg or 30 mg once daily (20 pts) | Child-Pugh A; (15 pts); Child-Pugh B; (5 pts) | PVT | Adverse events of grades 3/4 according to Common Terminology Criteria for Adverse Events version 4.0 | 3 *vs* 2 (*P =* 0.335) |
| Warfarin; (30 pts) | Child-Pugh A; (15 pts); Child-Pugh B; (10 pts); Child-Pugh C; (5 pts) |
| De Gottardi *et al*[83] | Rivaroxaban (30 pts); Dabigatran; (4 pts); Apixaban; (2 pts) | Mean 6 | PVT (22 pts); Budd Chiari syndrome (5 pts); Cardiac Arrhythmia (5 pts); DVT (2 pts); Other (2 pts) | Major bleeding | 1 |
|  |  |  |  | Minor bleeding | 4 |
| Intagliata *et al*[84] | Apixaban 5 mg or 2.5 mg twice daily or; Rivaroxaban 20 mg or 10 mg daily; (20 pts) | Child A; (9 pts); Child B; (11 pts) | PVT (12 pts); Non-splanchnic VTE (4 pts); Atrial fibrillation (4 pts) | Major bleeding | 1 *vs* 2 (*P =* 0.6) |
| LMWH or VKA (19 pts) | Child A; (9 pts); Child B; (10 pts) | Moderate bleeding | 1 *vs* 1 |
| Mild event | 2 *vs* 1 |
| Hum *et al*[85] | Rivaroxaban 15 mg daily (17 pts); Apixaban 5 mg twice daily; (10 pts) | Child A; (11 pts); Child B; (12 pts); Child C; (4 pts) | PVT (4 pts); DVT (12 pts); Atrial fibrillation (15 pts) | Major bleeding | 1 *vs* 5 (*P =* 0.03) |
| LMWH or WKA (18 pts) | Child A; (7 pts); Child B; (9 pts); Child C; (2 pts) | Moderate bleeding | 4 *vs* 5 (*P =* 0.45) |
| Mild bleeding | 3 *vs* 0 (*P =* 0.26) |
| Goriacko *et al*[91] | Dabigatran; (35 pts); Rivaroxaban (29 pts); Apixaban; (11 pts) | Child A; (48 pts); Child B; (26 pts); Child C; (1 pts) | Atrial fibrillation | Major bleeding | 3.3% *vs* 3.9% (p=No significance); |
| Warfarin (158) | Child A; (56 pts); Child B; (93 pts); Child C; (9 pts) |

PVT: Portal vein thrombosis; DVT: Deep vein thrombosis; VTE: Venous thromboembolism; LMWH: Low molecular weight heparin; VKA: Vitamin K antagonist.

**Table 2 Efficacy of direct oral anticoagulants in portal vein thrombosis treatment in cirrhosis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Drug administrated (*n* of patients)** | **Duration of treatment** | **PVT type** | **Results (cases *vs* controls)** |
| Ai *et al*[87] | Prospective cohort study | Rivaroxaban 20 mg once daily; (26 pts) | 6 mo | Chronic PVT; | At 3 mo:; Complete/partial recanalization: 5 *vs* 0 (*P =* 0.026); At 6 mo:; Complete/partial recanalization: 11 *vs* 1 (*P =* 0.003) |
| Dabigatran 150 mg twice daily (14 pts) | 6 mo |
| No treatment; (40 pts) |  |
| Hanafy *et al*[88] | Randomized, controlled, interventional, open-label study | Rivaroxaban 10 mg twice daily (40 pts) | Until recanalization and prolonged for 1 or 2 mo in complete recanalization of PVT which non-involvement/ involvement of SMV and for 6 mo in case of positive thrombogenic assay or partial recanalization; | Acute PVT | Complete recanalization: 34 *vs* 18 (*P =* 0.001); Partial recanalization: 6 *vs* 0 (*P =* 0.001) |
| Warfarin; (40 pts) |
| Nagaoki *et al*[86] | Retrospective cohort study | Edoxaban 60 mg or 30 mg once daily; (20 pts) | 6 mo | PVT | Complete recanalization: 14 *vs* 6 (*P* < 0.001); Partial recanalization: 4 *vs* 3 (*P =* 0.312) |
| Warfarin; (30 pts) |

PVT: Portal vein thrombosis.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**